Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
Sterile Urea is an injectable osmotic agent approved in 1976 as an NDA by Pfizer. It is used to reduce intracranial and intraocular pressure by creating an osmotic gradient. The drug works through osmotic diuresis, drawing fluid from tissues into the intravascular space.
As a legacy injectable nearing loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on cost management and specialty distribution rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke
Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
Trigeminal Brainstem Mapping 2: Higher Cortical Strucureas as Well as Subnuclei of the Spinal Trigeminal Nucleus
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Worked on STERILE UREA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Pfizer is hiring 1 role related to this product
Working on Sterile Urea offers limited career growth given its LOE-approaching lifecycle and zero linked job openings; this role is best suited for professionals comfortable managing mature, niche injectable products in specialty markets. Expect focus on cost containment, channel optimization, and customer retention rather than innovation or expansion.